Shares of Aptose Biosciences Inc. (NASDAQ:APTO) (TSE:APS) have been given a consensus recommendation of “Buy” by the eight ratings firms that are presently covering the stock, Marketbeat.com reports. Two analysts have rated the stock with a hold rating and six have issued a buy rating on the company. The average 12 month target price among brokers that have updated their coverage on the stock in the last year is $6.40.
A number of equities research analysts have weighed in on the company. Zacks Investment Research downgraded Aptose Biosciences from a “buy” rating to a “hold” rating in a research report on Tuesday, January 8th. HC Wainwright set a $9.00 price target on Aptose Biosciences and gave the company a “buy” rating in a research report on Thursday, December 13th. Citigroup assumed coverage on Aptose Biosciences in a research report on Friday, January 25th. They set an “outperform” rating and a $6.00 price target on the stock. Oppenheimer assumed coverage on Aptose Biosciences in a research report on Thursday, January 24th. They set an “outperform” rating and a $6.00 price target on the stock. Finally, Royal Bank of Canada assumed coverage on Aptose Biosciences in a research report on Friday, March 1st. They set an “outperform” rating and a $6.00 price target on the stock.
In other news, Director Erich Platzer sold 20,000 shares of Aptose Biosciences stock in a transaction dated Tuesday, March 19th. The stock was sold at an average price of $2.19, for a total value of $43,800.00. The transaction was disclosed in a filing with the SEC, which is available at this link. Also, CFO Gregory K. Chow acquired 15,000 shares of the firm’s stock in a transaction dated Wednesday, March 13th. The stock was bought at an average price of $1.75 per share, for a total transaction of $26,250.00. Following the acquisition, the chief financial officer now owns 122,014 shares of the company’s stock, valued at approximately $213,524.50. The disclosure for this purchase can be found here.
NASDAQ:APTO opened at $1.85 on Tuesday. Aptose Biosciences has a 52-week low of $1.57 and a 52-week high of $4.55.
Aptose Biosciences (NASDAQ:APTO) (TSE:APS) last posted its quarterly earnings data on Tuesday, March 12th. The biotechnology company reported ($0.17) earnings per share (EPS) for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.16) by ($0.01). Sell-side analysts predict that Aptose Biosciences will post -0.72 earnings per share for the current fiscal year.
Aptose Biosciences Company Profile
Aptose Biosciences Inc, a clinical-stage biotechnology company, discovers and develops personalized therapies addressing unmet medical needs in oncology in Canada. Its lead clinical program is APTO-253, which is a Phase I clinical trial for the treatment of patients with relapsed or refractory hematologic malignancies.
Read More: How to Invest in a Bull Market
Receive News & Ratings for Aptose Biosciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Aptose Biosciences and related companies with MarketBeat.com's FREE daily email newsletter.